All In Biotech

Drug Trial Radar · NCT04203056

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

15

Actual

Start

Dec 16, 2019

Primary completion

Oct 1, 2022

Study completion Oct 1, 2022

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alkermes, Inc.
First posted
Dec 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder, Depressive Type
  • Schizophreniform Disorder

Interventions

  • Aripiprazole LauroxilDrug

    12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through

  • ARI-ORALDrug

    oral aripiprazole

  • AL-NCDDrug

    Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Exacerbation or Relapse of Psychotic SymptomsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.